The mitotic checkpoint kinase BUB1 is a direct and actionable target of MYB in adenoid cystic carcinoma.

3D assay Adenoid cystic carcinoma BAY1816032 BUB1 ChIP sequencing MYB PDX RNA sequencing head and neck cancer

Journal

FEBS letters
ISSN: 1873-3468
Titre abrégé: FEBS Lett
Pays: England
ID NLM: 0155157

Informations de publication

Date de publication:
19 Dec 2023
Historique:
revised: 16 10 2023
received: 28 06 2023
accepted: 08 11 2023
medline: 19 12 2023
pubmed: 19 12 2023
entrez: 19 12 2023
Statut: aheadofprint

Résumé

Adenoid cystic carcinoma (ACC) is a head and neck cancer that frequently originates in salivary glands, but can also strike other exocrine glands such as the breast. A key molecular alteration found in the majority of ACC cases is MYB gene rearrangements, leading to activation of the oncogenic transcription factor MYB. In this study, we used immortalised breast epithelial cells and an inducible MYB transgene as a model of ACC. Molecular profiling confirmed that MYB-driven gene expression causes a transition into an ACC-like state. Using this new cell model, we identified BUB1 as a targetable kinase directly controlled by MYB, whose pharmacological inhibition caused MYB-dependent synthetic lethality, growth arrest and apoptosis of patient-derived cells and organoids.

Identifiants

pubmed: 38112379
doi: 10.1002/1873-3468.14786
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

This article is protected by copyright. All rights reserved.

Auteurs

Ylenia Cicirò (Y)

Centre for Inflammation Research and Translational Medicine (CIRTM).

Denise Ragusa (D)

Centre for Genomic Engineering and Maintenance (CenGEM), Department of Life Sciences, Brunel University London, UB8 3PH, Uxbridge, UK.

Paloma Tejera Nevado (PT)

Sahlgrenska Center for Cancer Research Department of Pathology, University of Gothenburg SE-405 30, Gothenburg, Sweden.

Rossano Lattanzio (R)

Center for Advanced Studies and Technology (CAST); Department of Innovative Technologies in Medicine & Dentistry, University of Chieti-Pescara 66110, Italy.

Gianluca Sala (G)

Center for Advanced Studies and Technology (CAST); Department of Innovative Technologies in Medicine & Dentistry, University of Chieti-Pescara 66110, Italy.

Tessa DesRochers (T)

Kiyatec, Greenville, SC, 29601, USA.

Melissa Millard (M)

Kiyatec, Greenville, SC, 29601, USA.

Mattias K Andersson (MK)

Sahlgrenska Center for Cancer Research Department of Pathology, University of Gothenburg SE-405 30, Gothenburg, Sweden.

Göran Stenman (G)

Sahlgrenska Center for Cancer Research Department of Pathology, University of Gothenburg SE-405 30, Gothenburg, Sweden.

Arturo Sala (A)

Centre for Inflammation Research and Translational Medicine (CIRTM).

Classifications MeSH